NexEos Bio
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
640 Lee Rd Ste 115, Wayne, Pennsylvania,...Phone Number
(610) 457-9891Website
www.nexeosbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NexEos Bio
NexEos Bio is dedicated to developing innovative technologies for the identification and treatment of eosinophil and cationic protein-mediated inflammation. Their lead therapeutic program, NTX-1024, is a topical solution aimed at treating eosinophil-driven ocular diseases, while their diagnostic program, NDX-3324, is a non-invasive imaging agent for Eosinophilic Esophagitis. The company is committed to improving the quality of life for patients suffering from eosinophil-related diseases. With a focus on urgency and innovation, NexEos Bio strives to provide better solutions for managing debilitating conditions.Explore more
Popular SearchesNexEos BioNexEos Diagnostics IncNexEos DiagnosticsNexEosNexeosbioSIC Code 87,873NAICS Code 54,541Show more
NexEos Bio Org Chart
TM
Co-Founder & Chief Business Officer & Chief E...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NexEos Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NexEos Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if NexEos Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on NexEos Bio recently announced quarterly report
NexEos Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at NexEos Bio
Funding: Get notified immidiatlly once NexEos Bio has new funding data
Click to see if NexEos Bio had a recent Job posting/layoffs
Product Launch: Get notified when NexEos Bio launches new products
Recommended Actions
Reach out to Masked Content who joined NexEos Bio as Masked Content
Find 2 more new buyers
Compare Similar Companies to NexEos Bio
Compare insights from companies similar to NexEos Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NexEos Bio
<$5M
1-10
Private
<$5M
2019
AR
Antonio RegaladoVice President, Business Alignment Quality Assurance, Regulatory Affairs & Compliance
Company Profile Activity
Activity Insights
NexEos Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NexEos Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NexEos Bio.
NexEos Bio financials insights
Gather financial insights about NexEos Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$3M
NexEos Bio Tech Stack
A closer look at the technologies used by NexEos Bio
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NexEos Bio
Sign Up For FreeTo access detailed company insights
NexEos Bio is dedicated to developing innovative technologies for the identification and treatment of eosinophil and cationic protein-mediated inflammation. Their lead therapeutic program, NTX-1024, is a topical solution aimed at treating eosinophil-driven ocular diseases, while their diagnostic program, NDX-3324, is a non-invasive imaging agent fo... Read More
